Reinhard Koenig - Oasmia Pharmaceutical Chief Officer

OASMYDelisted Stock  USD 0.06  0.00  0.00%   

Insider

Reinhard Koenig is Chief Officer of Oasmia Pharmaceutical AB
Age 63
Phone46 18 50 54 40
Webhttps://www.vivesto.com

Oasmia Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of (0.0875) % which means that it has lost $0.0875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2542) %, meaning that it generated substantial loss on money invested by shareholders. Oasmia Pharmaceutical's management efficiency ratios could be used to measure how well Oasmia Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Bashir HajjarAerCap Holdings NV
56
Emmanuel HerinckxAerCap Holdings NV
47
John BurkeAerCap Holdings NV
54
Cheryl TurnbullGriffon
60
Rita ForstAerCap Holdings NV
65
James SightGriffon
65
Patrick RankinAvis Budget Group
54
Stacey CartwrightAerCap Holdings NV
57
A WilsonTrio Tech International
95
Joseph CFAAerCap Holdings NV
N/A
Bernardo HeesAvis Budget Group
54
Christopher DurborowGriffon
N/A
Risteard SheridanAerCap Holdings NV
50
Thomas GibbonsGriffon
N/A
Srinivasan AnithaTrio Tech International
44
Vanessa WolczakAvis Budget Group
N/A
Siew SoonTrio Tech International
61
Jerome CobenGriffon
76
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. Vivesto Ab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 17 people. Oasmia Pharmaceutical AB [OASMY] is a Pink Sheet which is traded between brokers as part of OTC trading. Oasmia Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Oasmia Pharmaceutical Leadership Team

Elected by the shareholders, the Oasmia Pharmaceutical's board of directors comprises two types of representatives: Oasmia Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oasmia. The board's role is to monitor Oasmia Pharmaceutical's management team and ensure that shareholders' interests are well served. Oasmia Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oasmia Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kai Wilkinson, Chief Officer
Urban Ekelund, IR Mang
Henrik Rnnberg, Chief Health
John Cosby, Head Affairs
Robert Maiorana, Head CFO
Dzianis Babrou, Head Devel
Christer MD, Acting Officer
Reinhard Koenig, Chief Officer
Johanna Rostin, Head Affairs
Maria Hagberg, Head Affairs

Oasmia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oasmia Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Oasmia Pink Sheet

If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities